CN113813224A - Novel azelaic acid gel and preparation method thereof - Google Patents
Novel azelaic acid gel and preparation method thereof Download PDFInfo
- Publication number
- CN113813224A CN113813224A CN202010570378.0A CN202010570378A CN113813224A CN 113813224 A CN113813224 A CN 113813224A CN 202010570378 A CN202010570378 A CN 202010570378A CN 113813224 A CN113813224 A CN 113813224A
- Authority
- CN
- China
- Prior art keywords
- azelaic acid
- novel
- gel
- urea
- propylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 title claims abstract description 126
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000001879 gelation Methods 0.000 title description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims abstract description 45
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 44
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000004202 carbamide Substances 0.000 claims abstract description 24
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000008367 deionised water Substances 0.000 claims abstract description 14
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 14
- 238000010438 heat treatment Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000003973 paint Substances 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 35
- 206010000496 acne Diseases 0.000 abstract description 35
- 239000000047 product Substances 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 3
- 239000002244 precipitate Substances 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- QAWLWCKCAGRDSK-UHFFFAOYSA-N NC(=O)N.C(CCCCCCCC(=O)O)(=O)O Chemical compound NC(=O)N.C(CCCCCCCC(=O)O)(=O)O QAWLWCKCAGRDSK-UHFFFAOYSA-N 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000003932 Betula Nutrition 0.000 description 1
- 241000219429 Betula Species 0.000 description 1
- 240000003690 Callicarpa japonica Species 0.000 description 1
- 235000017595 Callicarpa japonica Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 230000036619 pore blockages Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a novel azelaic acid gel and a preparation method thereof, belonging to the field of skin medicaments. The technical problem to be solved by the invention is to provide a novel azelaic acid gel, which comprises the following components in percentage by weight: 10-20% of azelaic acid, 0.5-2% of salicylic acid, 1-3% of ZEN, 50-73% of 1, 3-propylene glycol, 1-25% of urea and the balance of deionized water. Compared with the azelaic acid gel product without urea, the novel azelaic acid gel prepared by adopting the specific raw materials has better transparency, no precipitate, good stability, more refreshing skin feel, no separation of azelaic acid particles and better skin permeation. Can be used for treating or preventing acne, and improving the cure rate of acne patients.
Description
[ technical field ] A method for producing a semiconductor device
The invention relates to a novel azelaic acid gel and a preparation method thereof, belonging to the field of skin medicaments.
[ background of the invention ]
Acne is a chronic inflammatory skin disease of a pilosebaceous unit, mainly occurs to teenagers, has great influence on the psychology and the social interaction of the teenagers, and can be naturally relieved or healed after adolescence. The clinical manifestations are marked by the polymorphic skin lesions of face, such as acne, papule, pustule, and nodule.
According to the joint investigation of the national dermatosis association and the national teenager association, the following results are shown: the incidence of acne in China is on the trend of rising year by year, and more than 80% of people have the problem of acne in different degrees.
For the treatment of acne, patients with mild or moderate acne generally choose not to be treated or choose acne removing products on the market for treatment, and patients with severe acne can go to hospitals and acne removing institutions for treatment. The existing acne removing mechanism and product on the market can not completely remove acnes and have side effects. The acne removing in hospitals is not specific, the acne removing in beauty parlors is not professional, and according to the authority statistics of the Ministry of health of China, the complete cure rate of the acne in China is only 32.95 percent. Therefore, there is an urgent need for a drug that can improve the cure rate of acne.
Azelaic acid, also known as azelaic acid, is a white to yellowish monoclinic prism, acicular crystals or powder in appearance. Has antibacterial effect, and can directly inhibit and kill bacteria on skin surface and in hair follicle; competitively inhibiting the enzyme process producing dihydrotestosterone and reducing excessive skin oil induced by dihydrotestosterone; inhibiting the generation and action of active oxygen free radicals, and resisting inflammation. It is used for treating acne, rosacea, and pigmentation disorder. Has good permeability to skin, and can increase absorption function of skin. However, since it is easily decomposed at high temperature, it is not preferable to add it at high temperature when it is used. It is easily soluble in hot water, alcohol and part of polyhydric alcohol, and slightly soluble in cold water, ether and benzene.
At present, azelaic acid products are often made into paste, for example, patent application numbers 201610786026.2, 201210230433.7. Patent application No. 201810825807.7 for making gel.
Some of the patents make azelaic acid into paste products, which have heavy skin feel and poor permeability; the product prepared into the gel has poor stability, and azelaic acid particles are separated out at low temperature, so the improvement is needed.
[ summary of the invention ]
Aiming at the defects, the technical problem solved by the invention is to provide a novel azelaic acid gel, compared with cream, the gel is free of oily component addition, and urea component is added to complex azelaic acid to generate azelaic acid urea complex which is dissolved in propylene glycol, so that the stability of the novel azelaic acid gel is improved, and the urea belongs to a humectant which can enhance the hydration force of the horny layer of skin, increase the permeability of the medicine and has good effect of preventing or treating acne. The invention relates to a novel azelaic acid gel, which consists of the following components in percentage by weight: 10-20% of azelaic acid, 0.5-2% of salicylic acid, 1-3% of ZEN, 50-73% of 1, 3-propylene glycol, 1-25% of urea and the balance of deionized water.
Preferably, the novel azelaic acid gel consists of the following components in percentage by weight: 12-18% of azelaic acid, 12-23% of urea, 0.8-1.5% of salicylic acid, 1.5-2.5% of ZEN, 50-73% of 1, 3-propylene glycol and the balance of deionized water.
As a preferable scheme, the novel azelaic acid gel consists of the following components in percentage by weight: 15% of azelaic acid, 15% of urea, 2% of ZEN, 1% of salicylic acid, 55% of 1, 3-propylene glycol and 12% of deionized water.
The invention solves the second technical problem by providing the preparation method of the novel azelaic acid gel.
The invention relates to a preparation method of a novel azelaic acid gel, which comprises the following steps:
a. dispersing ZEN in 1, 3-propylene glycol, then uniformly mixing with deionized water, and heating to 80-90 ℃ to obtain gel A;
b. uniformly dispersing azelaic acid and urea in 1, 3-propylene glycol, and heating to 65-80 ℃ to obtain a transparent solution B;
c. dispersing salicylic acid in 1, 3-propylene glycol, and heating until the salicylic acid is dissolved to obtain a transparent solution C;
d. and mixing the gel A, the solution B and the solution C, stirring and uniformly mixing at 55-85 ℃, and then cooling to room temperature to obtain the novel azelaic acid gel.
Wherein, there is no time sequence among step a, step b and step c, step a may be performed first, step b may be performed first, step c may be performed first, or the three steps may be performed simultaneously. The gel A, the solution B and the solution C are mixed and stirred evenly at last.
The novel azelaic acid gel provided by the invention can be used for treating or preventing acne, so that the cure rate of acne patients is improved, and facial skin injury of the patients caused by the acne is reduced, thereby relieving physiological and psychological pains of the patients caused by the acne. Meanwhile, the treatment cost of the patient is reduced, and the medical expense is reduced.
Compared with the prior art, the invention has the following beneficial effects:
compared with the azelaic acid gel product without urea, the novel azelaic acid gel prepared by adopting the specific raw materials has better transparency, no precipitate, good stability, more refreshing skin feel, no separation of azelaic acid particles and better skin permeation. Can be used for treating or preventing acne, and improving the cure rate of acne patients.
The novel azelaic acid gel of the invention is a formula (relative cream) without oil component addition. After the oily skin is used, the burden on the skin is not increased, pores are not blocked, and the hidden danger of acne is not generated; for the skin with acne, because of the strong penetration of urea and azelaic acid, the gel-like azelaic acid is simpler and easier than the paste-like penetration, and does not need more grease for dissolution and penetration assistance, thereby avoiding the corresponding side effect caused by the excessive introduction of oily substances; in the later anti-acne period, the follicular canal needs to be unblocked to facilitate the discharge of grease and other metabolites, azelaic acid is used for diminishing inflammation and sterilizing, the follicular canal is unblocked, the discharge problem is solved smoothly, and the possibility of recurrence of acne is reduced.
The novel azelaic acid gel provided by the invention has the advantages of simple components, antibacterial effect, simple preparation method and low cost.
[ detailed description ] embodiments
The invention relates to a novel azelaic acid gel, which consists of the following components in percentage by weight: 10-20% of azelaic acid, 0.5-2% of salicylic acid, 1-3% of ZEN, 50-73% of 1, 3-propylene glycol, 1-25% of urea and the balance of deionized water.
Wherein ZEN is polyacrylate cross-linked polymer-6, produced by French Saibek corporation, under the trade name Sepimax ZEN.
Salicylic acid is a fat-soluble organic acid, is white crystalline powder, exists in willow bark, beautyberry leaves and betula in nature, can be used as a cosmetic preservative, has the functions of removing sweat odor, relieving itching and swelling, relieving pain and diminishing inflammation and the like besides the functions of antisepsis and sterilization, can soften and peel off cutin and reduce pore blockage, and has a good effect on adolescent acne and common acne, and the dosage of the salicylic acid is preferably 0.5-2%. A specific amount of salicylic acid is mixed with azelaic acid, which has a synergistic effect and can improve the treatment effect of acne.
Urea is a good moisturizing ingredient, exists in the horny layer of the skin, and belongs to the main ingredient of the natural moisturizing factor NMF of the skin. Urea has the effects of moisturizing the skin and softening the cutin, so that the problem of acne can be solved by preventing the stratum corneum from blocking the pores. In the invention, azelaic acid and urea are subjected to a complex reaction when heated in a propylene glycol solution to generate an azelaic acid-urea complex which is easily dissolved in the propylene glycol solution, so that the stability of the formula is increased, and the urea is used as a moisture retention component to improve the moisture retention and make the skin feel fresh.
Preferably, the novel azelaic acid gel consists of the following components in percentage by weight: 12-18% of azelaic acid, 12-23% of urea, 0.8-1.5% of salicylic acid, 1.5-2.5% of ZEN, 50-73% of 1, 3-propylene glycol and the balance of deionized water.
As a preferable scheme, the novel azelaic acid gel consists of the following components in percentage by weight: 15% of azelaic acid, 15% of urea, 2% of ZEN, 1% of salicylic acid, 55% of 1, 3-propylene glycol and 12% of deionized water.
The invention solves the second technical problem by providing the preparation method of the novel azelaic acid gel.
The invention relates to a preparation method of a novel azelaic acid gel, which comprises the following steps:
a. dispersing ZEN in 1, 3-propylene glycol, then uniformly mixing with deionized water, and heating to 80-90 ℃ to obtain gel A;
b. uniformly dispersing azelaic acid and urea in 1, 3-propylene glycol, and heating to 65-80 ℃ to obtain a transparent solution B;
c. dispersing salicylic acid in 1, 3-propylene glycol, and heating until the salicylic acid is dissolved to obtain a transparent solution C;
d. and mixing the gel A, the solution B and the solution C, stirring and uniformly mixing at 55-85 ℃, and then cooling to room temperature to obtain the novel azelaic acid gel.
Wherein, there is no time sequence among step a, step b and step c, step a may be performed first, step b may be performed first, step c may be performed first, or the three steps may be performed simultaneously. The gel A, the solution B and the solution C are mixed and stirred evenly at last.
The novel azelaic acid gel provided by the invention can be used for treating or preventing acne, so that the cure rate of acne patients is improved, and facial skin injury of the patients caused by the acne is reduced, thereby relieving physiological and psychological pains of the patients caused by the acne. Meanwhile, the treatment cost of the patient is reduced, and the medical expense is reduced.
The following examples are provided to further illustrate the embodiments of the present invention and are not intended to limit the scope of the present invention. The raw materials used in the examples were:
ZEN: purchased from french seebeck;
urea: purchased from west longus science, inc;
azelaic acid: purchased from inspiring science and technology development ltd in Shanghai;
salicylic acid: purchased from remote chemical agents, ltd, Tianjin;
1, 3-propanediol: corn sources, available from dupont, usa;
example 1
A novel azelaic acid gel is prepared according to the following steps:
a. dispersing ZEN in 1, 3-propylene glycol, then uniformly mixing with deionized water, and heating to 80-90 ℃ to obtain gel A;
b. uniformly dispersing azelaic acid and urea in 1, 3-propylene glycol, and heating to 65-80 ℃ to obtain a transparent solution B;
c. dispersing salicylic acid in 1, 3-propylene glycol, and heating until the salicylic acid is dissolved to obtain a transparent solution C;
d. and mixing the gel A, the solution B and the solution C, stirring and uniformly mixing at 55-85 ℃, and then cooling to room temperature to obtain the novel azelaic acid gel.
Wherein the formula of each raw material is shown in table 1.
TABLE 1
Example 2 and comparative examples 1 to 2 are shown in Table 2.
TABLE 2
When the samples of examples 1 to 2 and comparative examples 1 to 2 were placed in a refrigerator and observed at a temperature of 5 ℃ for 1 month, it was found that examples 1 to 2 remained transparent, whereas comparative examples 1 to 2 had granular azelaic acid crystals precipitated, indicating that the samples produced according to examples 1 to 2 had good stability.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention, and all equivalent changes and modifications made based on the features and principles described in the claims of the present invention are included in the scope of the present invention.
Claims (4)
1. A novel azelaic acid gel comprises the following components by weight percent: 10-20% of azelaic acid, 0.5-2% of salicylic acid, 1-3% of ZEN, 50-73% of 1, 3-propylene glycol, 1-25% of urea and the balance of deionized water.
2. The novel azelaic acid gel of claim 1 wherein: the paint consists of the following components in percentage by weight: 12-18% of azelaic acid, 12-23% of urea, 0.8-1.5% of salicylic acid, 1.5-2.5% of ZEN, 50-73% of 1, 3-propylene glycol and the balance of deionized water.
3. The novel azelaic acid gel of claim 1 wherein: the paint consists of the following components in percentage by weight: 15% of azelaic acid, 15% of urea, 2% of ZEN, 1% of salicylic acid, 55% of 1, 3-propylene glycol and 12% of deionized water.
4. The preparation method of the novel azelaic acid gel as claimed in any one of claims 1 to 3, which is characterized by comprising the following steps:
a. dispersing ZEN in 1, 3-propylene glycol, then uniformly mixing with deionized water, and heating to 80-90 ℃ to obtain gel A;
b. uniformly dispersing azelaic acid and urea in 1, 3-propylene glycol, and heating to 65-80 ℃ to obtain a transparent solution B;
c. dispersing salicylic acid in 1, 3-propylene glycol, and heating until the salicylic acid is dissolved to obtain a transparent solution C; d. and mixing the gel A, the solution B and the solution C, stirring and uniformly mixing at 55-85 ℃, and then cooling to room temperature to obtain the novel azelaic acid gel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010570378.0A CN113813224A (en) | 2020-06-19 | 2020-06-19 | Novel azelaic acid gel and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010570378.0A CN113813224A (en) | 2020-06-19 | 2020-06-19 | Novel azelaic acid gel and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113813224A true CN113813224A (en) | 2021-12-21 |
Family
ID=78912289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010570378.0A Pending CN113813224A (en) | 2020-06-19 | 2020-06-19 | Novel azelaic acid gel and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113813224A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116370325A (en) * | 2023-03-23 | 2023-07-04 | 上海科黛生物科技有限公司 | Transparent azelaic acid gel and preparation method and application thereof |
-
2020
- 2020-06-19 CN CN202010570378.0A patent/CN113813224A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116370325A (en) * | 2023-03-23 | 2023-07-04 | 上海科黛生物科技有限公司 | Transparent azelaic acid gel and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3708152B1 (en) | Azelaic acid gel, and preparation method and application thereof | |
| US6780439B2 (en) | Wound treatment solution and method for using same | |
| CN101569640A (en) | Application of total asiaticoside to preparation of medicaments or cosmetics for preventing and curing striae gravidarum | |
| US7655255B2 (en) | Topical composition for transdermal administration | |
| US20060222689A1 (en) | Skin care compositions and methods | |
| CN113332162A (en) | protamine-PDRN compound, composition and application in preparation of skin care product | |
| Aliasl et al. | Comparing the healing effects of Arnebia euchroma ointment with petrolatum on the ulcers caused by fractional CO2 laser: a single-blinded clinical trial | |
| JPH1135475A (en) | Preparation containing roripa nasturtium-aquaticum extract and used for external use | |
| CN113813224A (en) | Novel azelaic acid gel and preparation method thereof | |
| CN108295191A (en) | A kind of acne-removing composition and preparation method thereof inhibiting Propiobacterium | |
| CN102872158B (en) | External drug combination for curing eczema and preparation method thereof | |
| CN105497537A (en) | Medicine composition with skin whitening and tendering functions and preparing method thereof | |
| CN103536450B (en) | Anti-acne external product and effective ingredient preparation method thereof | |
| EP1752132A2 (en) | Skin cosmetic compositions | |
| CN114767590A (en) | Scar and acne mark removing beauty lotion and preparation method and application thereof | |
| CN105031254B (en) | A kind of paste and preparation method thereof for treating dermatitis | |
| CN105168360A (en) | Compound plant extract liniment for treating acne and preparation method of compound plant extract liniment | |
| CN110812377A (en) | Acne treatment and repair composition and application thereof | |
| KR960004897B1 (en) | Process for preparing acne remedial agent comprising ginseng extraction and centella asiatica extraction | |
| CN110897921B (en) | Acne-removing skin care product containing regenerative medical materials and preparation method thereof | |
| RU2182822C1 (en) | Method and graphite-selenium complex for treating the patients suffering from inflammatory and trophic skin disorders | |
| CN105833251A (en) | Hand and foot chapping nursing composition and preparing method thereof | |
| JP2001206820A (en) | Preparation for external use for treating acne | |
| CN116870081A (en) | Composition for preventing and treating radiotherapy and chemotherapy related skin mucosa injury and application thereof | |
| CN112791093A (en) | Transdermal drug delivery composition for treating acne and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211221 |